Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2a + interleukin-2
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Interferon alfa-2a + interleukin-2 is a combination immunotherapy regimen that utilizes two cytokines to stimulate the immune system against cancer cells. Interferon alfa-2a enhances the immune response by increasing the activity of natural killer cells and macrophages, while interleukin-2 promotes the growth and activity of T cells. This combination has been studied extensively in clinical trials for metastatic renal cell carcinoma, melanoma, and other advanced cancers, with varying administration routes including intravenous and subcutaneous delivery.
- Other names
- IFN alpha + IL-2IFN-α-2a + IL-2sc-IFN-α-2a + sc-IL-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alfa-2a + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2a + interleukin-2.